{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:21:15Z","timestamp":1777321275839,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clinthera.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T11:46:44Z","timestamp":1694864804000},"page":"1105-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Riccobene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Calafiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uros","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.08.010_bib0001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/jcm12010085","article-title":"Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review","volume":"12","author":"Castillon","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0003","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent Advances in the Diagnosis and Management of Gaucher Disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0004","article-title":"Enzyme Replacement and Substrate Reduction Therapy for Gaucher Disease","volume":"2015","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2230-8210.83402","volume":"15","author":"Bohra","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher Disease: Progress and Ongoing Challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0007","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","article-title":"Eliglustat: First Global Approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the Use of Eliglustat in the Treatment of Adults with Gaucher Disease Type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0009","doi-asserted-by":"crossref","unstructured":"Bennett, L.L.; Turcotte, K. Eliglustat Tartrate for the Treatment of Adults with Type 1 Gaucher Disease. Drug Des Devel Ther 2015, 9, 4639, doi:10.2147\/DDDT.S77760.","DOI":"10.2147\/DDDT.S77760"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 Months of Eliglustat Therapy in Treatment-Na\u00efve Adults with Gaucher Disease Type 1: The Phase 3 ENGAGE Trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0011","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical Outcomes after 4.5 Years of Eliglustat Therapy for Gaucher Disease Type 1: Phase 3 ENGAGE Trial Final Results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.chroma.2017.10.038","article-title":"Optimization of Ultra-High Pressure Liquid Chromatography - Tandem Mass Spectrometry Determination in Plasma and Red Blood Cells of Four Sphingolipids and Their Evaluation as Biomarker Candidates of Gaucher's Disease","volume":"1525","author":"Chipeaux","year":"2017","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0013","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1005367328003","article-title":"Plasma Chitotriosidase Activity in Gaucher Disease Patients Who Have Been Treated Either by Bone Marrow Transplantation or by Enzyme Replacement Therapy with Alglucerase","volume":"20","author":"Young","year":"1997","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0014","doi-asserted-by":"crossref","unstructured":"de Mello, R.A.F.; Mello, M.B.N.; Pessanha, L.B. Magnetic Resonance Imaging and BMB Score in the Evaluation of Bone in Gaucher's Disease Patients. Radiol Bras 2015, 48, 216, doi:10.1590\/0100-3984.2014.0068.","DOI":"10.1590\/0100-3984.2014.0068"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0015","doi-asserted-by":"crossref","unstructured":"Robertson, P.L.; Maas, M.; Goldblatt, J.; Pl, R.; Goldblatt, M.M.; Robertson, P.L. Semiquantitative Assessment of Skeletal Response to Enzyme Replacement Therapy for Gaucher's Disease Using the Bone Marrow Burden Score. 2007, doi:10.2214\/AJR.06.1410.","DOI":"10.2214\/AJR.06.1410"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0016","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate Reduction Therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0017","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/ajh.25875","article-title":"Real-world Effectiveness of Eliglustat in Treatment-na\u00efve and Switch Patients Enrolled in the International Collaborative Gaucher Group Gaucher Registry","volume":"95","author":"Mistry","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0018","first-page":"29","article-title":"Incremental Biomarker and Clinical Outcomes after Switch from Enzyme Therapy to Eliglustat Substrate Reduction Therapy in Gaucher Disease","author":"Kleytman","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0019","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.3390\/jcm11216265","article-title":"Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy","volume":"11","author":"Istaiti","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0020","article-title":"Safety and Efficacy of Eliglustat Combined to Enzyme Replacement Therapy for Lymphadenopathy in Patients with Gaucher Disease Type 3","volume":"31","author":"Lee","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1515\/cclm-2019-0949","article-title":"LC-MS\/MS Analysis of Plasma Glucosylsphingosine as a Biomarker for Diagnosis and Follow-up Monitoring in Gaucher Disease in the Spanish Population","volume":"58","author":"Ir\u00fan","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated Plasma Glucosylsphingosine in Gaucher Disease: Relation to Phenotype, Storage Cell Markers, and Therapeutic Response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a Reliable Biomarker in Gaucher Disease: A Narrative Review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0025","first-page":"228","article-title":"La Chitotriosidasi: Un Marker per La Diagnosi Ed Il Follow-up Della Malattia Di Gaucher","volume":"26","author":"Barone","year":"2022","journal-title":"RIVISTA ITALIANA DI PEDIATRIA"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0026","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/01.ATV.0000089329.09061.07","article-title":"Serum Chitotriosidase Activity Is Increased in Subjects With Atherosclerosis Disease","volume":"23","author":"Artieda","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.5114\/aoms.2016.60093","article-title":"Increased Chitotriosidase Activity in Plasma of Patients with Type 2 Diabetes","volume":"12","author":"Zurawska-Plaksej","year":"2016","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01961-8","article-title":"Increased Chitotriosidase 1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy","volume":"16","author":"Freigang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0029","article-title":"Chitotriosidase: A Biomarker of Activity and Severity in Patients with Sarcoidosis","volume":"21","author":"Bennett","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s42000-022-00409-3","article-title":"High Chitotriosidase and AGE Levels in Acromegaly: A Case-Control Study","volume":"22","author":"Ozisik","year":"2023","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0031","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat Maintains Long-Term Clinical Stability in Patients with Gaucher Disease Type 1 Stabilized on Enzyme Therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.08.010_bib0032","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat Compared with Imiglucerase in Patients with Gaucher's Disease Type 1 Stabilised on Enzyme Replacement Therapy: A Phase 3, Randomised, Open-Label, Non-Inferiority Trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823003120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:20Z","timestamp":1758963620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823003120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0149291823003120"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.08.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}